Uploads Contact
/
Login Upload

  • Search Results for 'Guidance Purposes'

Cross ward
Cross ward
lindy-dunigan
Guidance for Industry Developing Products for Weight Management DRAFT GUIDANCE This guidance
Guidance for Industry Developing Products for Weight Management DRAFT GUIDANCE This guidance
stefany-barnette
Guidance for Industry How to Comply with the Pediatric Research Equity Act DRAFT GUIDANCE
Guidance for Industry How to Comply with the Pediatric Research Equity Act DRAFT GUIDANCE
trish-goza
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs
pamella-moone
Guidance for Industry Applications for Premarket Review of New Tobacco Products DRAFT
Guidance for Industry Applications for Premarket Review of New Tobacco Products DRAFT
myesha-ticknor
Guidance for Industry Complicated Intra Abdominal Infections Developing Drugs for Treatment
Guidance for Industry Complicated Intra Abdominal Infections Developing Drugs for Treatment
kittie-lecroy
Guidance for Industry Contract Manufacturing Arrangements for Drugs Quality Agreements
Guidance for Industry Contract Manufacturing Arrangements for Drugs Quality Agreements
tawny-fly
Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA DRAFT GUIDANCE
Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA DRAFT GUIDANCE
conchita-marotz
Informed Consent Information Sheet Guidance for IRBs Clinical Investigators and Sponsors
Informed Consent Information Sheet Guidance for IRBs Clinical Investigators and Sponsors
cheryl-pisano
Guidance for Industry Considerations for the Design of Early Phase Clinical Trials of
Guidance for Industry Considerations for the Design of Early Phase Clinical Trials of
briana-ranney
ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits
ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits
pasty-toler
Guidance for Industry Naming of Drug Products Containing Salt Drug Substances DRAFT GUIDANCE
Guidance for Industry Naming of Drug Products Containing Salt Drug Substances DRAFT GUIDANCE
karlyn-bohler
stributed for comment purposes onlyComments and suggestions regarding
stributed for comment purposes onlyComments and suggestions regarding
natalia-silvester
Guidance for Industry Assessment of Abuse Potential of Drugs DRAFT GUIDANCE This guidance
Guidance for Industry Assessment of Abuse Potential of Drugs DRAFT GUIDANCE This guidance
ellena-manuel
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product DRAFT
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product DRAFT
mitsue-stanley
Guidance for Industry Chronic Fatigue Syndrome Myalgic Encephalomyelitis Developing Drug
Guidance for Industry Chronic Fatigue Syndrome Myalgic Encephalomyelitis Developing Drug
pamella-moone
This guidance document is being distributed for comment purposes only.
This guidance document is being distributed for comment purposes only.
lindy-dunigan
This guidance document is being distributed for comment purposes only.
This guidance document is being distributed for comment purposes only.
myesha-ticknor
This guidance document is being distributed for comment purposes only.
This guidance document is being distributed for comment purposes only.
debby-jeon
This guidance document is being distributed for comment purposes only.
This guidance document is being distributed for comment purposes only.
pasty-toler
This guidance document is being distributed for comment purposes only.
This guidance document is being distributed for comment purposes only.
tatiana-dople
This guidance document is being distributed for comment purposes only.
This guidance document is being distributed for comment purposes only.
tatiana-dople
This guidance document is being distributed for comment purposes only.
This guidance document is being distributed for comment purposes only.
stefany-barnette
This guidance document is being distributed for comment purposes only.
This guidance document is being distributed for comment purposes only.
conchita-marotz